107555-38-4

Basic information

• Product Name: Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate
• Synonyms: 6,8-Difluoro-4-hydroxy-quinoline-3-carboxylic acid ethyl ester Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate
• CAS NO: 107555-38-4
• Molecular Formula: C12H9F2NO3
• Molecular Weight: 253.2
• Product Categories: blocks;Carboxes;FluoroCompounds;Quinolines
• Mol File: 107555-38-4.mol

Chemical Properties

• Boiling Point: 340ºC at 760 mmHg
• Flash Point: 159.4ºC
• Appearance: /
• Density: 1.386g/cm3
• Vapor Pressure: 8.85E-05mmHg at 25°C
• Refractive Index: 1.537
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate(107555-38-4)
• EPA Substance Registry System: Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate(107555-38-4)

Safety Data

• Hazardous Substances Data: 107555-38-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate is used as a key intermediate in the synthesis of various drugs due to its versatile chemical properties. Its anti-bacterial, anti-inflammatory, and anti-cancer properties make it a valuable ingredient in the development of new medications aimed at treating a range of diseases and conditions.
Used in Antibacterial Applications:
In the field of infectious diseases, Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate is employed as an antibacterial agent, leveraging its ability to combat bacterial infections effectively. Its incorporation into pharmaceutical formulations helps in the development of antibiotics and other treatments to counteract bacterial resistance.
Used in Anti-inflammatory Applications:
Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate is also used as an anti-inflammatory agent, contributing to the management of inflammation-related conditions. Its presence in pharmaceutical products can help reduce inflammation and alleviate symptoms associated with various inflammatory diseases.
Used in Anti-cancer Applications:
Furthermore, Ethyl 6,8-difluoro-4-hydroxyquinoline-3-carboxylate is utilized as an anti-cancer agent, playing a role in the development of chemotherapeutic drugs. Its potential to target and inhibit the growth of cancer cells makes it a promising component in oncology, offering new avenues for cancer treatment and management.

InChI:InChI=1/C12H9F2NO3/c1-2-18-12(17)8-5-15-10-7(11(8)16)3-6(13)4-9(10)14/h3-5H,2H2,1H3,(H,15,16)

Upstream product

• 367-25-9 2,4-difluorophenylamine 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 101830-90-4 diethyl 2-((2,4-difluorophenylamino)methylene)malonate 

Downstream Products

• 150258-20-1 ethyl 4-chloro-6,8-difluoroquinoline-3-carboxylate 

Relevant articles and documents

Synthesis and preliminary anti-inflammatory and anti-bacterial evaluation of some diflunisal aza-analogs

Our aim was to identify new multi-target compounds endowed with both anti-inflammatory and anti-bacterial activities for treatment of human infections. Diflunisal, a nonsteroidal anti-inflammatory agent, has recently been repurposed for its anti-virulence properties against methicillin-resistant Staphylococcus aureus. Effective synthesis of some aza-analogs of the anti-inflammatory drug diflunisal was carried out following the route involving key oxazole intermediates to obtain o- and m-hydroxypyridinecarboxylic acid derivatives. The newly synthesized diflunisal aza-analogs did not exhibit cytotoxic activity up to 80 μM and some of them exhibited anti-inflammatory activities, decreasing the levels of pro-inflammatory cytokines and prostaglandins induced by bacterial lipopolysaccharide in human primary macrophages. Ten of the diflunisal aza-analogs were found to have interesting antibacterial activity, sensitizing S. aureus, Streptococcus pyogenes, Enterococcus faecium, and Pseudomonas aeruginosa to the antibacterial effects of beta-lactam antibiotics and protein synthesis inhibitors.

Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors

Thirty-two quinoline derivatives were designed and synthesized as HIV-1 Tat-TAR interaction inhibitors. All the compounds showed high antiviral activities in inhibiting the formation of SIV-induced syncytium in CEM174 cells. Nine of them with low cytotoxicities were evaluated by Tat dependent HIV-1 LTR-driven CAT gene expression colorimetric enzyme assay in human 293T cells, indicating effective inhibitory activities of blocking the Tat-TAR interaction. Molecular modeling experiments indicated that these compounds may inhibit Tat-TAR interaction by binding to Tat protein instead of TAR RNA.